Balyasny Asset Management L.P. Takes $322,000 Position in DaVita Inc. (NYSE:DVA)

Balyasny Asset Management L.P. purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,154 shares of the company's stock, valued at approximately $322,000.

Other large investors have also recently bought and sold shares of the company. Epoch Investment Partners Inc. acquired a new position in shares of DaVita during the 4th quarter worth about $55,100,000. Invesco Ltd. increased its position in shares of DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after acquiring an additional 275,284 shares during the last quarter. Amundi boosted its holdings in shares of DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the last quarter. Bridgewater Associates LP raised its holdings in shares of DaVita by 298.4% in the 4th quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock valued at $35,888,000 after purchasing an additional 179,744 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in DaVita by 256.8% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock valued at $24,301,000 after purchasing an additional 116,758 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on DVA shares. StockNews.com raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Truist Financial decreased their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday. Cowen restated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. Finally, Barclays upped their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $164.50.

DaVita Stock Performance

NYSE:DVA traded down $4.86 during trading on Wednesday, reaching $140.91. The company's stock had a trading volume of 665,164 shares, compared to its average volume of 829,660. DaVita Inc. has a 12 month low of $131.44 and a 12 month high of $179.60. The firm has a 50 day moving average of $145.81 and a 200-day moving average of $153.54. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a market cap of $10.64 billion, a price-to-earnings ratio of 13.12, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The firm had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The company's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business earned $2.26 earnings per share. Research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.